AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33394323
Drug: Solriamfetol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol treatment for 12 weeks
Trial: 35120890
Drug: Inhaled diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled diesel exhaust (DE) at 300 μg PM2.5/m3 for 2 hours
Trial: 35120890
Drug: Inhaled diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled diesel exhaust (DE) at 20, 50, or 150 μg PM2.5/m3 for 4 hours
Trial: 35120890
Drug: Inhaled diesel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled diesel exhaust (DE)
Trial: 35051725
Drug: Cisplatin-gemcitabine (CG)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-gemcitabine (CG) followed by gemcitabine (G) maintenance for patients with objective response (OR) or switch to pemetrexed (P) for patients with stable disease (SD)
Trial: 36101997
Drug: Rutin 500
RxNorm normalized name: rutin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rutin 500 mg per day for 3 months
Trial: 33884889
Drug: High-sensitivity cardiac
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity cardiac troponin I ≥5 ng/L
Trial: 33884889
Drug: BNP ≥100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP ≥100 pg/mL
Trial: 33884889
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-sensitivity cardiac troponin I ≥5 ng/L and BNP ≥100 pg/mL
Trial: 34263472
Drug: Edasalonexent (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edasalonexent (100 mg or 250 mg softgel capsules)
Trial: 32651292
Drug: 200/50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/50 mg dispersible levodopa‐benserazide (dopaminergic challenge)
Trial: 616689159
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy (specifics not provided)
Trial: 34952736
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 15 mg/kg
Trial: 34487722
Drug: Start oral
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start oral anticoagulation (101 participants)
Trial: 34487722
Drug: Avoid oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoid oral anticoagulation (102 participants)
Trial: 32964986
Drug: VASPIN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VASPIN treatment
Trial: 32964986
Drug: VASPIN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VASPIN treatment in HK-2 cells
Trial: 36113532
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 2-valent vaccine (Cervarix)
Trial: 36113532
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 9-valent vaccine (Gardasil 9)
Trial: 34310978
Drug: TVB-2640 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVB-2640 25 mg
Trial: 34310978
Drug: TVB-2640 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVB-2640 50 mg
Trial: 34595801
Drug: Slow deep
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow deep breathing (SDB) intervention, 20-minute video 5 times weekly for 4 weeks
Trial: 32720602
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) + Ezetimibe (10 mg/day)
Trial: 32720602
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) monotherapy
Trial: 32202256
Drug: Lopinavir/ritonavir combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir combination therapy for 14 days
Trial: 33455765
Drug: Propylene glycol
RxNorm normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propylene glycol (PG) at 15.0 μL/g of dry matter (TRT)
Trial: 33455765
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 μL/g of dry matter, CON)
Trial: 32337700
Drug: Low-dose nalmefene
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nalmefene (N1 group, n=40)
Trial: 32337700
Drug: High-dose nalmefene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nalmefene (N2 group, n=40)
Trial: 32337700
Drug: Low-dose nalmefene
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nalmefene (N1 group)
Trial: 32337700
Drug: High-dose nalmefene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nalmefene (N2 group)
Trial: 32876468
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (n=25)
Trial: 36041396
Drug: 0.45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/kg selenium-enriched yeast (SeY)
Trial: 34867233
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for CP
Trial: 35637515
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction (MBSR) program for 2.5 hours weekly for 8 weeks
Trial: 33434080
Drug: Fortified low-fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified low-fat yogurt (1500 IU nano encapsulated vitamin D3 per 150 g/d)
Trial: 33434080
Drug: Fortified low-fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified low-fat milk (1500 IU nano encapsulated vitamin D3 per 200 g/d)
Trial: 32167784
Drug: Direct Service
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Service Model (6 sessions over 22 weeks of pharmacotherapy followed by behavior training)
Trial: 35503446
Drug: Capsaicin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (1.5 μg)
Trial: 33882541
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose TXA (30 mg/kg loading dose followed by 10 mg/kg/h infusion)
Trial: 33882541
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose TXA (10 mg/kg loading dose followed by 1 mg/kg/h infusion)
Trial: 33882541
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose TXA
Trial: 33882541
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose TXA
Trial: 38670610
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins
Trial: 36196609
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA COVID-19 vaccine
Trial: 32607749
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (0.125, 0.250, or 0.500 million international units (MIU)/m2, given daily for 5 days and then fortnightly for 1 year)
Trial: 32607749
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (0.250 and 0.500 MIU m−2 day−1)
Trial: 36350332
Drug: Gamified mobile
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamified mobile application for somatosensory training (daily use for 4 weeks)
Trial: 33559636
Drug: Incisional Negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional Negative Pressure Wound Therapy (INPWT)
Trial: 33414824
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional rehabilitation therapy)
Trial: 35222903
Drug: Nicotinamide 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide 1000 mg once daily for 12 weeks
Trial: 35222903
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antidiabetic therapy only)
Trial: 35594970
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behavior therapy (CBT) program with 8 modules and 8, 30-minute telephone sessions with a therapist (n = 45)
Trial: 36171040
Drug: Integrated GP-paediatrician
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated GP-paediatrician model of care (weekly co-consultation sessions, monthly case discussions, phone and email support)
Trial: 35073986
Drug: Resistant potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant potato starch (RPS), 15 g per day
Trial: 35073986
Drug: Cornstarch (digestible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cornstarch (digestible starch control), 15 g per day
Trial: 34863332
Drug: Lenzilumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenzilumab (600 mg per dose, three doses delivered 8 hours apart)
Trial: 36194764
Drug: NG/CT treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG/CT treatment records (n = 30,365)
Trial: 36194764
Drug: Treatment records
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment records associated with gonorrhea and/or chlamydia (n = 67,895)
Trial: 36194764
Drug: Testing episodes
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testing episodes not associated with treatment records (n = 122,694)
Trial: 36194764
Drug: Same-day treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day treatment for NG/CT testing episodes
Trial: 32780636
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine injection (0.2% lidocaine in sterile water)
Trial: 33780506
Drug: Simple information
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple information treatment (explained that added sugars information was now available on the NF label)
Trial: 33780506
Drug: Full information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full information treatment (included additional details on interpreting added sugars content and associated diseases)
Trial: 34043051
Drug: Foot massage
RxNorm normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot massage during chemotherapy (4 sessions, 7 min each foot, 40 min intervals)
Trial: 32954737
Drug: Initial surgery
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial surgery followed by adjuvant chemotherapy
Trial: 32954737
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by cytoreductive surgery
Trial: 33306556
Drug: Enhanced-prophylaxis (fluconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced-prophylaxis (fluconazole 100 mg/day, azithromycin, isoniazid, cotrimoxazole)
Trial: 34289879
Drug: Community-based health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based health educational intervention administered by Female Community Health Volunteers (FCHVs)
Trial: 32346711
Drug: Topical doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical doxycycline for 5 min before replantation
Trial: 36361001
Drug: Task-oriented activities
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Task-oriented activities of daily living (T-ADL) training
Trial: 36082909
Drug: Enterally delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enterally delivered glutamine (0.5 g/kg/day)
Trial: 32048768
Drug: Each additional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each additional cycle of treatment
Trial: 35686212
Drug: Domiciliary nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domiciliary nasal high flow (NHF) therapy
Trial: 34397699
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment regimens
Trial: 33761873
Drug: Cadmium concentrations
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadmium concentrations (0, 15, 30, 45, and 60 mg L-1) for 60 days
Trial: 34000676
Drug: License suspension
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: License suspension
Trial: 36350591
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 to 20 mg, flexibly dosed) for 8 weeks
Trial: 37813418
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment group
Trial: 34779114
Drug: One-stage surgical
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage surgical protocol without ridge augmentation (Group A)
Trial: 34779114
Drug: Two-stage surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage surgical protocol with ridge augmentation (Group B)
Trial: 35843520
Drug: Tralokinumab (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab (monotherapy or in combination with topical corticosteroids)
Trial: 35435639
Drug: Tramadol (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100-300 mg/day)
Trial: 35803302
Drug: Ventilatory strategy
RxNorm normalized name: VENTILATOR FILTER,THERMOFLO #6000S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilatory strategy to prevent atelectasis (VESPA) with endotracheal intubation, recruitment maneuver, FiO2 titration (<100%), and PEEP of 8-10 cm H2O
Trial: 34887855
Drug: Matrix M
RxNorm normalized name: Matrix metallopeptidase 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix M adjuvanted H5N1 vaccine (30μg)
Trial: 34887855
Drug: Matrix M
RxNorm normalized name: Matrix metallopeptidase 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix M adjuvanted H5N1 vaccine (7.5μg)
Trial: 34887855
Drug: Matrix M
RxNorm normalized name: Matrix metallopeptidase 9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix M adjuvanted H5N1 vaccine (1.5μg)
Trial: 34887855
Drug: Non-adjuvanted H5N1
RxNorm normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted H5N1 vaccine (30μg)
Trial: 33930091
Drug: Medication reviews
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reviews
Trial: 34544393
Drug: e-health treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-health treatment for urinary incontinence
Trial: 35442343
Drug: Terlipressin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1 mg IV bolus q 4 hourly for 2 days) in TG2 group
Trial: 35442343
Drug: Terlipressin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (1 mg IV bolus q 4 hourly for 5 days) in TG5 group
Trial: 35442343
Drug: Control (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.9% normal saline, 10 mL IV bolus q 4 hourly) in TG0 group
Trial: 33612059
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance (dose-escalated 2.5–10mg, 20/28 days per cycle for six months)
Trial: 32430450
Drug: ETC120' (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETC120' (10 mg THC and 200 mg CBD)
Trial: 35120753
Drug: Sustained-release pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release pediatric melatonin (PRM)
Trial: 35395220
Drug: Ileal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileal glucose infusion (30g glucose and 3g 3-O-methylglucose)
Trial: 35599504
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus proprioception training (PTR-PT)
Trial: 35599504
Drug: Modified Constraint-Induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Constraint-Induced Movement Therapy (PTR-mCIMT)
Trial: 35599504
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (PTR)
Trial: 34521084
Drug: Platelet nadir
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet nadir <100 × 10^3/?L
Trial: 35705194
Drug: 9 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g/day perilla oil (HOI)
Trial: 35705194
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day perilla oil (LOI)
Trial: 35899772
Drug: Early antiplatelet
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early antiplatelet treatment with 300 mg clopidogrel and 100 mg aspirin
Trial: 32796301
Drug: Biosilicate conical
RxNorm normalized name: calcium aluminum borosilicate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosilicate conical implants
Trial: 36288885
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) full dose (400 mg TID)
Trial: 36288885
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) reduced dose (200 mg TID)
Trial: 36332503
Drug: Sub-dissociative dose
RxNorm normalized name: DAB(SUB 389)IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-dissociative dose ketamine (SDK)
Trial: 33256540
Drug: Expressed self-contempt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressed self-contempt during brief psychiatric treatment
Trial: 32048083
Drug: Tofacitinib continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib continuous treatment (10 mg twice daily)
Trial: 32048083
Drug: Tofacitinib interrupted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib interrupted treatment (withdrawn for 2 weeks, then reinitiated)
Trial: 35240317
Drug: NO3‐ supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO3‐ supplementation (140 ml of concentrated NO3‐ beetroot juice, 9.7 mmol, 0.6 gm NO3‐)
Trial: 34077643
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg intravenously every 2 weeks for up to 1 year)
Trial: 35213469
Drug: Intraoperative medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative medications prescribed based on pharmacogenomic results.
Trial: 35213469
Drug: Total medications
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total medications prescribed considering pharmacogenomic results.
Trial: 35213469
Drug: Genomically high-risk
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomically high-risk medications administered.
Trial: 35213469
Drug: Genomically cautionary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genomically cautionary medications administered.
Trial: 36884054
Drug: Subcutaneous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous nitroglycerin
Trial: 34274016
Drug: Psychosocial Navigator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial Navigator (PSN) intervention with monthly screening results and tailored recommendations for psychosocial distress and mental health symptoms.
Trial: 36355991
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNT-A) treatment (10U-25U for temporalis muscle and 30U-75U for masseter muscle)
Trial: 36355991
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNT-A) treatment
Trial: 33165612
Drug: SPECTRUM investigational
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECTRUM investigational cigarettes (15.8 mg/g)
Trial: 33165612
Drug: SPECTRUM investigational
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECTRUM investigational cigarettes (5.2 mg/g)
Trial: 33165612
Drug: SPECTRUM investigational
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECTRUM investigational cigarettes (2.4 mg/g)
Trial: 33165612
Drug: SPECTRUM investigational
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPECTRUM investigational cigarettes (1.3 mg/g)